Hemophilia Clinical Development Landscape Strengthens as 80+ Companies Drive Innovation | DelveInsight

Hemophilia Pipeline

DelveInsight’s latest report, “Hemophilia Pipeline Insight, 2026” offers a detailed evaluation of the evolving Hemophilia pipeline, highlighting the contributions of more than 80 companies and over 80 investigational therapies. The report presents an extensive overview of pipeline drug candidates across both clinical and preclinical stages, along with a thorough assessment based on product type, development phase, route of administration, and molecular classification. Additionally, it sheds light on discontinued and inactive programs within the Hemophilia research ecosystem.

Access the full Hemophilia Pipeline Report to explore cutting-edge therapeutic advancements: https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight

Key Highlights from the Hemophilia Pipeline Analysis

Recent developments underscore the rapid progress in Hemophilia research:

• February 11, 2026: Novo Nordisk A/S announced an ongoing study evaluating Mim8 in patients with Hemophilia A, both with and without inhibitors. Mim8 is designed to prevent bleeding episodes by mimicking the function of missing clotting factor VIII (FVIII). The study duration may extend up to 5.5 years depending on enrollment timing.
• February 05, 2026: Pfizer initiated a long-term study to assess the safety, efficacy, and tolerability of marstacimab as a prophylactic therapy in patients previously enrolled in Phase III trials.
• February 05, 2026: CSL Behring launched a Phase III multicenter trial to evaluate CSL222 (AAV5-hFIXco-Padua) gene therapy in adolescent males with severe to moderately severe Hemophilia B.
• February 05, 2026: Hoffmann-La Roche began a Phase I/II trial investigating NXT007, focusing on safety, pharmacokinetics, pharmacodynamics, and therapeutic efficacy in patients with moderate to severe Hemophilia A.

The report highlights a highly dynamic and competitive landscape, with numerous stakeholders actively working to introduce innovative treatment options for Hemophilia.

Download free sample report: https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight

Leading Companies in the Hemophilia Space

A wide range of biopharmaceutical companies are advancing Hemophilia therapies, including:

Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk, and others.

Prominent Emerging Therapies

Several promising pipeline candidates are shaping the future of Hemophilia treatment, such as:

NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601, Fitusiran, Marstacimab, BPA prophylaxis, Concizumab, and PF-06741086.

Explore a comprehensive analysis of ongoing clinical trials and breakthroughs: Hemophilia Clinical Trials and Studies

Detailed Profiles of Key Emerging Drugs

SerpinPC – Centessa Pharmaceuticals

SerpinPC is an innovative therapy targeting activated protein C (APC) for both Hemophilia A and B. Clinical data suggest favorable tolerability and a reduction in bleeding episodes. Its pharmacokinetic profile supports infrequent subcutaneous administration, potentially eliminating the need for traditional factor replacement therapies. The drug has demonstrated promising results in Phase IIa trials with validated genetic targeting.

Fitusiran – Alnylam Pharmaceuticals

Fitusiran is an RNA interference (RNAi)-based therapy administered subcutaneously, targeting antithrombin to rebalance hemostasis. Developed in collaboration with Sanofi Genzyme, it is currently in Phase III clinical trials and represents a novel approach to treating Hemophilia and rare bleeding disorders.

ASC618 – ASC Therapeutics

ASC618 is a gene therapy candidate utilizing an AAV8 vector to treat Hemophilia A. It incorporates a liver-specific promoter and a bioengineered FVIII variant, significantly enhancing FVIII production compared to conventional approaches. Preclinical studies indicate improved durability and reduced cellular stress. The therapy has received IND clearance from the U.S. FDA, and a Phase I/II trial is planned to evaluate its safety and efficacy.

Comprehensive Insights Offered in the Report

The Hemophilia Pipeline Insight report provides:

• A detailed overview of companies actively developing Hemophilia therapies
• Segmentation of pipeline candidates into early, mid, and late stages of development
• Analysis of both active and inactive research programs
• Evaluation based on route of administration, mechanism of action, target receptor, and therapy type
• Insights into monotherapies and combination approaches
• In-depth coverage of collaborations, licensing deals, and funding activities shaping the market

Gain strategic insights into unmet needs and innovation trends in Hemophilia: Hemophilia Clinical Trials and FDA Approvals

Therapeutic Segmentation by Route of Administration

Pipeline therapies are categorized across multiple delivery methods, including:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type Classification

The report also classifies therapies based on molecular composition, such as:

• Oligonucleotides
• Peptides
• Small molecules

Scope of the Hemophilia Pipeline Report

• Geographical Coverage: Global
• Key Companies: Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk, among others
• Key Pipeline Therapies: Mim8, Fitusiran, Marstacimab, Concizumab, PF-06741086, and others
• Therapeutic Assessment: By product type (monotherapy, combination, both)
• Development Stages: Discovery, Preclinical, Phase I, Phase II, Phase III

Discover which companies are leading innovation in Hemophilia drug development: Hemophilia Emerging Drugs and Major Companies

Hemophilia Pipeline Report Structure

The report is structured to provide a holistic understanding of the Hemophilia pipeline and includes:

• Introduction
• Executive Summary
• Disease Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Analytical Perspective
• Late-stage, mid-stage, and early-stage product profiles
• Preclinical and discovery-stage insights
• Inactive pipeline analysis
• Key companies and products
• Unmet needs and market dynamics
• Future outlook and expert analyst views

About DelveInsight

DelveInsight is a premier healthcare market research and consulting firm specializing in life sciences. The company delivers high-quality, data-driven insights to help organizations make informed strategic decisions. With deep domain expertise and a global perspective, DelveInsight empowers clients with actionable intelligence, enabling them to stay competitive and capitalize on emerging opportunities in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 09650213330
Address:428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
City: New Delhi
State: India
Country: India
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services